TrialArthritis research & therapy2019

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.

Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.